Locations:
Search
Questions remain about the merits of asparaginase-based therapy
A retrospective analysis
Offers a new option for patients 60 and older with relapsed/refractory disease
Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Study assesses the impact of donor source and post-transplant prophylaxis for patients receiving a hematopoietic cell transplant
Novel regimen may help overcome the shortcomings of traditional chemotherapy in geriatric population
Key findings from national database study
Drug beats standard care for the treatment of relapsed or refractory ALL
A deep dive into survival differences between pediatric and adolescent/young adult leukemia patients
Advertisement
Advertisement